TICKERNERD
Menu
PHRPHRHealthcare · Health Information Services

PHR Stock Forecast: Phreesia, Inc. Price Predictions for 2026-2027

Last close, 17 Sept 2026
$10
+0.39% on the day

The 19 Wall Street analysts covering Phreesia, Inc. hold a median 12-month price target of $14 — +31.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 51 of 100 as at 17 Sept 2026 — in the upper half.

Market cap
$637.5M
Ticker Nerd rank
51 / 100
Median analyst target
$14
Analysts covering
19
Revenue$129.5M+10.4% y/y
Operating income$7.6M
Net income$1.9M
Free cash flow$13.8M
Quarterly, 8 quarters to 31 July 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+1.1%
1M
−11.2%
YTD
−39.2%
1Y
−55.8%
From 52W high
−58.4%
From 52W low
+27.5%
$8
$25
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

PHR stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Phreesia, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 17 Sept 2026
51 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
91
Value
79
Growth
70
Accruals
63
Size
51
Revisions
45
Volatility
42
Issuance
18
Momentum
10

Quality (91): The business earns solid, repeatable profits on what it owns.

Momentum (10): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

PHR stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PHR, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$15$20$25Oct 25Jan 26Apr 26Jul 26PHRHigh $20Median $14Low $10

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says19 analysts
10 Buy9 Hold0 Sell
Low $10Median $14High $20

The green dot is the last close — the median target sits +31.3% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 4 moved their price target up and 2 moved it down.

DateFirmActionRatingTarget
8 Sept 2026Raymond JamesDowngradeMarket Perform—
4 Sept 2026BairdMaintainsNeutral$10 → $11
4 Sept 2026DA DavidsonMaintainsBuy$14 → $13
3 Sept 2026Canaccord GenuityMaintainsBuy$16
3 Sept 2026Freedom Capital MarketsMaintainsBuy$14
3 Sept 2026NeedhamReiteratesBuy$14
3 Sept 2026RBC CapitalReiteratesOutperform$19
3 Sept 2026Wells FargoMaintainsEqual-Weight$9.00 → $10
31 Aug 2026NeedhamReiteratesBuy$14
31 Aug 2026NeedhamReiteratesBuy—
29 May 2026Truist SecuritiesMaintainsHold$11 → $12
29 May 2026Truist SecuritiesMaintainsHold—
28 May 2026Canaccord GenuityMaintainsBuy—
28 May 2026Canaccord GenuityMaintainsBuy$22 → $16
28 May 2026CitigroupMaintainsNeutral$10 → $12
28 May 2026CitigroupMaintainsNeutral—
28 May 2026DA DavidsonMaintainsBuy$14
28 May 2026DA DavidsonMaintainsBuy—
20 May 2026Wells FargoDowngradeEqual-Weight—
15 May 2026BarclaysDowngradeEqual-Weight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PHR appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

PHR vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 17 Sept 2026, Phreesia, Inc. returned −55.8% against +17.0% for the S&P 500, dividends included.

PHR vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120Oct 25Jan 26Apr 26Jul 26PHRS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

PHR analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−6.0%
Analysts raising
0
Analysts cutting
1
Fundamentals

Phreesia, Inc. (PHR) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
56.9×

Cheaper than 12% of US stocks

Price / sales
1.3×

Cheaper than 64% of US stocks

Price / book
1.8×

Cheaper than 49% of US stocks

EV / EBITDA
14.6×

Cheaper than 24% of US stocks

Growth & margins
Revenue growth (YoY)
10.4%

Higher than 53% of US stocks

Earnings growth (YoY)
193.3%

Higher than 90% of US stocks

Gross margin
66.6%

Higher than 80% of US stocks

Operating margin
5.9%

Higher than 57% of US stocks

Net margin
2.1%

Higher than 52% of US stocks

Returns & dividend
Return on equity
3.1%

Higher than 50% of US stocks

Return on assets
2.6%

Higher than 62% of US stocks

Dividend yield
21.9%

Higher than 94% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Phreesia, Inc. (PHR) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Phreesia, Inc. has a market value of $637.5M and an enterprise value of $637.4M.

  • Revenue in the twelve months to 31 July 2026: $507.8M. The latest quarter grew 10.4% year on year.

  • Net income over the same four quarters: $10.4M, a 2.1% net margin.

  • Diluted earnings per share, trailing twelve months: $0.17.

  • Free cash flow in the twelve months to 31 July 2026: $67.5M, after $13.2M of capital spending.

  • Shares outstanding: 62.0M.

  • Trailing P/E: 56.9×; forward P/E: 6.4× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 21.91%, paying out 0% of earnings.

  • Phreesia, Inc. employs 1,789 people — $284K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 31 July 2026 · market figures as at 16 Sept 2026

Data provided by Twelve Data

Peers

PHR vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelHealth Information Services
CompanyMarket capTKN rank
PHRPhreesia, Inc.$637.5M
51
WEAVWeave Communications, Inc.$586.4M
84
SOPHSOPHiA GENETICS SA$715.6M
49
CTEVClaritev Corp.$522.7M
65
NRCNRC Health$470.3M
93
HSTMHealthStream, Inc.$866.0M
95
CARLCarlsmed, Inc.$418.4M
29

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Phreesia, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest PHR news & analysis

Phreesia's ProviderConnect Audiences are Now Available in the DeepIntent Audience Marketplace

Business Wire · 14 Sept 2026neutral

Phreesia announced that its ProviderConnect audiences are now available in the DeepIntent Audience Marketplace. This expands the distribution of Phreesia's healthcare audience data through DeepIntent's platform.

Why it matters — A PHR watcher would care because the move broadens the reach of Phreesia's data offerings, potentially extending its advertising and audience product to a new marketplace channel.

Why Phreesia Stock Got Knocked Down Today

The Motley Fool · 9 Sept 2026negative

Phreesia's stock declined today amid lingering negative sentiment following the company's latest earnings release, as investors reacted negatively to the company missing its earnings expectations.

Why it matters — A PHR watcher would care because the stock's decline reflects investor disappointment over the company's latest earnings miss, which may signal ongoing concerns about its financial performance.

Why Phreesia Stock Tumbled Today

The Motley Fool · 3 Sept 2026negative

Phreesia's stock fell despite a sharp rise in net income, as results missed analysts' expectations. The company did slightly beat consensus estimates for revenue.

Why it matters — The stock decline despite an earnings beat on revenue signals that market watchers may be more focused on profit expectations for Phreesia.

These Analysts Revise Their Forecasts On Phreesia After Q2 Results

Benzinga · 3 Sept 2026neutral

Phreesia reported mixed second-quarter financial results on Wednesday. Following the results, analysts revised their forecasts for the company.

Why it matters — Analyst forecast revisions after Q2 results signal how the investment community is reassessing Phreesia's outlook.

Phreesia, Inc. (PHR) Q2 2027 Earnings Call Transcript

Seeking Alpha · 2 Sept 2026neutral

Seeking Alpha published the Q2 2027 earnings call transcript for Phreesia, Inc. (PHR). The item provides the transcript of the company's second-quarter 2027 earnings discussion.

Why it matters — A PHR watcher would want to review the transcript for management's commentary on the quarter's results and outlook.

FAQ

Frequently asked questions about PHR stock

What is the PHR stock price forecast for 2026-2027?

The 19 Wall Street analysts covering Phreesia, Inc. have a median 12-month price target of $14, with estimates ranging from $10 to $20. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is PHR stock a buy right now?

Of the 19 analysts covering Phreesia, Inc., 10 rate it a Buy, 9 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Phreesia, Inc. 51 out of 100 across roughly 4,600 US stocks as at 17 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank PHR?

As at 17 Sept 2026, Phreesia, Inc. ranks 51 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (91 of 100).

Will PHR stock go up?

No one can know that. What the data says: the median 12-month target from 19 analysts implies +31.3% from the last close, and Ticker Nerd's factor model ranks Phreesia, Inc. 51 out of 100 as at 17 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the PHR stock forecast for 2030?

No analyst covering Phreesia, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PHR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $20 over the next 12 months.

How has PHR stock performed over the past year?

Phreesia, Inc. returned -55.8% over the 12 months to 17 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Phreesia, Inc. do?

Phreesia Inc. is a healthcare technology company that provides an integrated software and payments platform for medical practices, health systems, and other healthcare organizations.

What is the latest news on PHR?

The most recent item we track (Business Wire, 14 Sept 2026): "Phreesia's ProviderConnect Audiences are Now Available in the DeepIntent Audience Marketplace". Phreesia announced that its ProviderConnect audiences are now available in the DeepIntent Audience Marketplace. This expands the distribution of Phreesia's healthcare audience data through DeepIntent's platform.

Company

About Phreesia, Inc.

Phreesia Inc. is a healthcare technology company that provides an integrated software and payments platform for medical practices, health systems, and other healthcare organizations. Its products support patient intake, registration, scheduling, eligibility verification, payments, and post-visit engagement, helping providers streamline front-office and administrative workflows. The company also offers patient activation, clinical assessments, and communication tools that help organizations capture information more efficiently and improve care coordination. Phreesia serves a wide range of healthcare customers, including ambulatory practices, specialty groups, hospitals, life sciences companies, and payers. Its platform is used across patient check-in and revenue cycle processes, making Phreesia a key provider of digital infrastructure in healthcare operations.

CEO Mr. Chaim Indig · 1,789 employees · United States · https://www.phreesia.com